Data Sheet (Cat.No.T17291)

TargetMol

ZK 216348

Chemical Properties



CAS No. : 669073-68-1

Formula: C24H23F3N2O5

Molecular Weight: 476.45

Storage: Keep away from moisture,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ZK 216348 is a non-steroidal selective glucocorticoid receptor agonist with an IC50 of 20.3 nM. ZK 216348 also binds to progesterone receptors and mineralocorticoid receptors with IC_{50} values of 20.4 nM and 79.9 nM, respectively, and may be useful for studying inflammatory bowel disease (IBD).
Targets(IC50)	Glucocorticoid Receptor,Progesterone Receptor
In vitro	In PBMCs, ZK 216348 can inhibit the production of TNF-α and IL-12, with IC50 values of 89 nM and 52 nM, respectively [1]. ZK 216348 significantly suppresses TNF-α-induced IL-8 expression levels in homo sapiens colorectal adenocarcinoma cells (Caco-2) [2].
In vivo	Following administration of ZK 216348 (1-30 mg/kg, subcutaneous injection, for 24 hours) to NMRI mice and Wistar rats, ear edema symptoms in both animal models were significantly suppressed. The study found that compared to the control drug, ZK 216348 demonstrated distinct advantages in terms of adverse reactions, specifically manifested in its inhibitory effects on blood glucose elevation and spleen atrophy, while also exhibiting a relatively milder impact on skin atrophy [1].

Solubility Information

Solubility	DMSO: ≥ 160 mg/mL,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0989 mL	10.4943 mL	20.9886 mL
5 mM	0.4198 mL	2.0989 mL	4.1977 mL
10 mM	0.2099 mL	1.0494 mL	2.0989 mL
50 mM	0.042 mL	0.2099 mL	0.4198 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Schäcke H, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):227-32.
Reuter KC, et al. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther. 2012 Apr;341(1):68-80.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481